messaggio

clik on the image and visit the new site

New site clik on the image

New site clik on the image

"In silico"


 From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.


Phage Therapy is influenced by:

Phage therapy is influenced by:

Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
 Mutation rate
Phenotypical delay
Phage cocktail

My point of view

Wednesday, 2 October 2013

After one year what's happened now about phage therapy ? Something must have happened.

1.
the project was launched on June 1st 2013 and will last 27 months

Comment: I am happy about this work but not for mycobacteriophage choice.The same phages are used in all works with mycobacteria (the host range for D29 is very large and includes both slow and fast-growing species). This aspect ( this is my opinion) is not a favourable point for phage therapy in Buruli: we must wait until a specific phage for Mycobacterium ulcerans strain is isolated together in the same country.
This work supports the timeliness of phage therapy before the infection to become chronic (33 days) and confirms my working hypothesis: a,b,c
Posted by Rodolfo Berretti at 17:45
Labels: